STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC

Bookmark and Share
Published: 15 Feb 2019
Views: 831
Rating:
Save
Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

Prof Andrew Armstrong speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about the STREAM trial investigating the use of enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in patients with high-risk PSA recurrent prostate cancer.

He explains that the trial studied nearly 40 men over a course of 6 months with enzalutamide and ADT with salvage radiation showing that 65% of men were free of disease and off therapy after 3 years.

Prof Armstrong states that the 2/3 year outcomes are superior to what would normally be expected suggesting that enzalutamide could be more effective in improving long term remission rates in these patients.